primary and 406 (36%) were secondary in which the patient had one or more previous breast augmentation procedures. Silicone gel implants were utilized in 471 (65%) of the primary and 324 (80%) of the secondary procedures. Operative technique involved a circumvertical or inverted-T mastopexy in 77% (n= 871) and a bilateral mastopexy in 93% of patients. The overall reoperation rate was 14.9% (13.2% of primary and 16.6% of secondary procedures) over a mean followup period of 43 months (range 4 months to 121 months). Tissue related complications consisting of recurrent or persistent ptosis and poor scaring were most common at 6.2% (n= 71). Implant related complications requiring a revision were most commonly a result of the patient's desire to change implant size 3.1% (n=36) and capsular contracture Baker III/IV in 2.8% (n= 32). There were no cases of periprosthetic infection requiring explantation and no significant skin flap necrosis (> 2cm) or nipple areolar loss noted.
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CONCLUSION:
One-stage augmentation mastopexy can be safely performed with a reoperation rate that is significantly lower than when the procedure is staged. The effectiveness of this procedure is defined by a low complication rate, acceptable aesthetic results, and by minimizing the number of operations for the patient. With appropriate patient selection and operative technique, acceptable outcomes can be achieved safely and effectively. 
METHODS:
A commercially available in-situ ELISA was standardized and validated for patients with confirmed BIA-ALCL diagnosis with clinical isolates and a laboratory strain. A panel of five pathologically confirmed BIA-ALCL patients were screened by serum, plasma, and peri-prosthetic effusion specimens and compared against serum, plasma, and non-neoplastic delayed seromas in six healthy control patients. Statistical analysis demonstrated assay consistency and reliability.
RESULTS: BIA-ALCL serum specimens and all control specimens were tested at full concentration, 1:100, 1:250, 1:500 and 1:1000 serial dilutions. All BIA-ALCL effusions demonstrated CD30 ELISA detection at full and all serial concentrations. BIA-ALCL plasma specimens were weakly positive at full concentration and no activity with serial dilution. BI-ALCL serum specimens and all control specimens were negative at all concentrations.
CONCLUSION: This is the first study to demonstrate a viable alternative to CD30 immunohistochemistry for the screening of BIA-ALCL. A CD30 ELISA represents a novel low-cost screening test, which may be used to screen suspicious aspirations of delayed periprosthetic fluid collections in an office-based setting. This preliminary study demonstrates reliability and efficacy, however prospective testing in an expanded cohort will be required to establish sensitivity and specificity.
Characterizing the Viscoelastic Behavior of Implant Silicone Gels under Physiological Conditions
Presenter: Bavand Keshavarz, PhD -3 to 628 rad/s) were performed at 25 o C. We report both the elastic or storage modulus of the material, Gʹ (a measure of the object's resistance to elastic deformations), and the loss modulus Gʹʹ (reflecting the viscous dissipation of energy).
RESULTS:
With increasing temperature, Allergan's cohesive gel demonstrated minimal change in its loss and elastic moduli. Allergan's highly cohesive gel showed a substantial increase in its elastic modulus (G' values showed 60% increase from 5 o C to 75 o C) and a negligible change in its loss modulus. Comparing the two companies' highly cohesive gels, Allergan's showed higher values of elastic modulus and higher sensitivity to temperature changes compared to Mentor's. The elastic modulus increased by 11% from room to body temperatures (25 o C-37 o C) for Allergan's highly cohesive gel while the Mentor sample showed only a 6% increase. The frequency sweep tests revealed that all four gels showed similar values of loss modulus, however the highly cohesive gels were more 10 times more elastic than the standard cohesive gels. The entire dynamic mechanical response of these gels can be modeled quantitatively by a four parameter rheological model, known as the Fractional Kelvin-Voigt model. 
INTRODUCTION:
Healthy individuals rarely have problems with wound healing. Most skin lesions heal rapidly and efficiently within one to two weeks. However, many medical and surgical complications can be attributed to deficiencies in wound repair. Open wounds have lost the barrier that protects tissues from bacterial invasion and allows the escape of vital fluids. Without expeditious healing, infections become more frequent. The CD24 gene encodes a heavily-glycosylated cell surface protein anchored to the membrane by phosphatidylinositol. CD24 plays an important role in the adaptive immune response and controls an important genetic checkpoint for homeostasis and autoimmune diseases in both mice and humans. We have previously shown that over expression of CD24 results in increased proliferation and migration rates, and that its deficiency leads to impaired wound healing.
